2hats
Dust.
Not really.Az is a bit shit on this stat
As stated multiple times before, the vaccines aim to prevent severe disease, not infection. They will reduce incidence of infection to varying degrees - from person to person and (gradually, decreasingly) over time. The important detail is that all the vaccines promote (in the healthy) a strong cellular immune response thereby greatly reducing the severity of disease and the risk of requiring medical assistance.
The measurements of (eg binding antibody units per unit volume) are steps on the ladder of standardisation towards correlates of protection such that vaccine development can be accelerated and emergency use authorisations granted based on phase 2 immunogenicity trials rather than time consuming and logistically complex phase 3 efficacy trials (which might struggle to meet their endpoints as more of the general population are vaccinated). This type of approval has already just happened in Taiwan (post #1413), though that was based on a relative comparison of immunogenicity with a previously approved vaccine that had proven results via phase 3 efficacy trials.